Key result
Welander distal myopathy stems from a specific TIA1 mutation causing progressive distal weakness.
Why the study?
Many aspects of Welander distal myopathy remain unknown, including underlying molecular mechanisms and factors driving phenotypic variability, and the scarcity of reliable disease models limits treatment development.
This review provides a comprehensive update on Welander distal myopathy, emphasizing the genetic basis, diagnostic approaches, and novel insights into systemic manifestations such as metabolic stress and beta-cell dysfunction.
May support TIA1 testing for suspected late-onset distal weakness; leaves open mechanisms, variability, and disease models.
Myopathies are a heterogeneous group of disorders that primarily affect skeletal muscles and are classified as rare diseases owing to their low incidence. In particular, Welander distal myopathy is a rare, late-onset muscular disorder that was first described in 1951. Since then, substantial progress has been made in characterizing its clinical presentation and histopathological features. Despite these advances, many aspects of the disease, such as the underlying molecular mechanisms and factors driving phenotypic variability, remain unknown. Furthermore, the scarcity of reliable disease models not only limits the exploration of the molecular basis of the disease but also the development of effective treatments. In this review, we summarize the current knowledge of Welander distal myopathy and discuss potential directions in this field.
No takes yet. Share an insight, caveat, or question.
García-Rubio et al. (2026) conducted a review in Welander distal myopathy. Welander distal myopathy is a rare, late-onset muscular disorder caused by a specific TIA1 gene mutation (p.E384K), characterized by progressive distal muscle weakness and cellular stress responses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: